Watch Demo

Human Microbiome Market Research Report by Disease, Technology, Product, Therapeutic Area, Application, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

Human Microbiome Market Research Report by Disease, Technology, Product, Therapeutic Area, Application, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030
  • Publish Date:January 2023

  • Number of Pages:134

  • Report ID:6397674

  • Format:PDF

  • Publisher:360iResearch

$ 3949

Summary

Human Microbiome Market Research Report by Disease (Acute Diarrhea, Autoimmune Disorders, and Cancer), Technology, Product, Therapeutic Area, Application, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

The United States Human Microbiome Market size was estimated at USD 261.49 million in 2022 and expected to reach USD 322.48 million in 2023, projecting growth at a CAGR of 23.87% to reach USD 1,449.98 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the United States Human Microbiome Market.

Cumulative Impact of Russia-Ukraine Conflict:

We continuously monitor and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the United States Human Microbiome Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The United States Human Microbiome Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the United States Human Microbiome Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group’s economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players’ strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the United States Human Microbiome Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Disease, the market is studied across Acute Diarrhea, Autoimmune Disorders, Cancer, Diabetes, Mental Disorders, and Obesity.

Based on Technology, the market is studied across 16s rRNA Sequencing, Cell Culture Technology, Computational Tools, High-Throughput Technology, Metagenomic Sequencing, and Omics Technology.

Based on Product, the market is studied across Diagnostic Devices, Drugs, Foods, and Prebiotic & Probiotics.

Based on Therapeutic Area, the market is studied across Gastrointestinal Disorders, Metabolic Disorders, Skin Disorders, and Women’s Health.

Based on Application, the market is studied across Diagnostics and Therapeutics.

Based on State, the market is studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the United States Human Microbiome Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The United States Human Microbiome Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The United States Human Microbiome Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The United States Human Microbiome Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Human Microbiome Market, including 4D pharma PLC, AOBiome, LLC, Astarte Medical Partners, Inc, Axial Therapeutics, Inc., DuPont de Nemours, Inc., Enterome Bioscience, Evelo Biosciences, Inc., Exeliom Biosciences SAS, Ferring B.V., Finch Therapeutics Group, Inc., Intralytix, Inc., Locus Biosciences, Inc., Merck and Co. Inc., Metabiomics Corporation, Osel Inc., Second Genome, Inc., Seres Therapeutics, Inc., Synlogic, Inc., Synthetic Biologics, Inc., Vedanta Biosciences, Inc., and Yakult Honsha Co., Ltd..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Human Microbiome Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Human Microbiome Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Human Microbiome Market?
4. What is the competitive strategic window for opportunities in the United States Human Microbiome Market?
5. What are the technology trends and regulatory frameworks in the United States Human Microbiome Market?
6. What is the market share of the leading vendors in the United States Human Microbiome Market?
7. What modes and strategic moves are considered suitable for entering the United States Human Microbiome Market?

Table of contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Human Microbiome Market, by Disease
6.1. Introduction
6.2. Acute Diarrhea
6.3. Autoimmune Disorders
6.4. Cancer
6.5. Diabetes
6.6. Mental Disorders
6.7. Obesity

7. Human Microbiome Market, by Technology
7.1. Introduction
7.2. 16s rRNA Sequencing
7.3. Cell Culture Technology
7.4. Computational Tools
7.5. High-Throughput Technology
7.6. Metagenomic Sequencing
7.7. Omics Technology

8. Human Microbiome Market, by Product
8.1. Introduction
8.2. Diagnostic Devices
8.3. Drugs
8.4. Foods
8.5. Prebiotic & Probiotics

9. Human Microbiome Market, by Therapeutic Area
9.1. Introduction
9.2. Gastrointestinal Disorders
9.3. Metabolic Disorders
9.4. Skin Disorders
9.5. Women's Health

10. Human Microbiome Market, by Application
10.1. Introduction
10.2. Diagnostics
10.3. Therapeutics

11. California Human Microbiome Market
11.1. Introduction

12. Florida Human Microbiome Market
12.1. Introduction

13. Illinois Human Microbiome Market
13.1. Introduction

14. New York Human Microbiome Market
14.1. Introduction

15. Ohio Human Microbiome Market
15.1. Introduction

16. Pennsylvania Human Microbiome Market
16.1. Introduction

17. Texas Human Microbiome Market
17.1. Introduction

18. Competitive Landscape
18.1. FPNV Positioning Matrix
18.1.1. Quadrants
18.1.2. Business Strategy
18.1.3. Product Satisfaction
18.2. Market Ranking Analysis, By Key Player
18.3. Market Share Analysis, By Key Player
18.4. Product Portfolio Analysis, By Key Player
18.5. Competitive Scenario
18.5.1. Merger & Acquisition
18.5.2. Agreement, Collaboration, & Partnership
18.5.3. New Product Launch & Enhancement
18.5.4. Investment & Funding
18.5.5. Award, Recognition, & Expansion

19. Company Usability Profiles
19.1. 4D pharma PLC
19.2. AOBiome, LLC
19.3. Astarte Medical Partners, Inc
19.4. Axial Therapeutics, Inc.
19.5. DuPont de Nemours, Inc.
19.6. Enterome Bioscience
19.7. Evelo Biosciences, Inc.
19.8. Exeliom Biosciences SAS
19.9. Ferring B.V.
19.10. Finch Therapeutics Group, Inc.
19.11. Intralytix, Inc.
19.12. Locus Biosciences, Inc.
19.13. Merck and Co. Inc.
19.14. Metabiomics Corporation
19.15. Osel Inc.
19.16. Second Genome, Inc.
19.17. Seres Therapeutics, Inc.
19.18. Synlogic, Inc.
19.19. Synthetic Biologics, Inc.
19.20. Vedanta Biosciences, Inc.
19.21. Yakult Honsha Co., Ltd.

20. Appendix
20.1. Discussion Guide
20.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES HUMAN MICROBIOME MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES HUMAN MICROBIOME MARKET SIZE, 2022 VS 2030
FIGURE 3. UNITED STATES HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 5. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. UNITED STATES HUMAN MICROBIOME MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 7. UNITED STATES HUMAN MICROBIOME MARKET DYNAMICS
FIGURE 8. UNITED STATES HUMAN MICROBIOME MARKET PORTER'S FIVE FORCES ANALYSIS
FIGURE 9. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2022 VS 2030 (%)
FIGURE 10. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES HUMAN MICROBIOME MARKET COMPETITIVE STRATEGIC WINDOW, BY DISEASE, 2030
FIGURE 12. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY ACUTE DIARRHEA, 2018-2030 (USD MILLION)
FIGURE 13. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
FIGURE 14. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
FIGURE 15. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
FIGURE 16. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY MENTAL DISORDERS, 2018-2030 (USD MILLION)
FIGURE 17. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY OBESITY, 2018-2030 (USD MILLION)
FIGURE 18. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
FIGURE 19. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES HUMAN MICROBIOME MARKET COMPETITIVE STRATEGIC WINDOW, BY TECHNOLOGY, 2030
FIGURE 21. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY 16S RRNA SEQUENCING, 2018-2030 (USD MILLION)
FIGURE 22. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY CELL CULTURE TECHNOLOGY, 2018-2030 (USD MILLION)
FIGURE 23. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY COMPUTATIONAL TOOLS, 2018-2030 (USD MILLION)
FIGURE 24. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY HIGH-THROUGHPUT TECHNOLOGY, 2018-2030 (USD MILLION)
FIGURE 25. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY METAGENOMIC SEQUENCING, 2018-2030 (USD MILLION)
FIGURE 26. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY OMICS TECHNOLOGY, 2018-2030 (USD MILLION)
FIGURE 27. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
FIGURE 28. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 29. UNITED STATES HUMAN MICROBIOME MARKET COMPETITIVE STRATEGIC WINDOW, BY PRODUCT, 2030
FIGURE 30. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD MILLION)
FIGURE 31. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
FIGURE 32. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY FOODS, 2018-2030 (USD MILLION)
FIGURE 33. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY PREBIOTIC & PROBIOTICS, 2018-2030 (USD MILLION)
FIGURE 34. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2022 VS 2030 (%)
FIGURE 35. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 36. UNITED STATES HUMAN MICROBIOME MARKET COMPETITIVE STRATEGIC WINDOW, BY THERAPEUTIC AREA, 2030
FIGURE 37. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2030 (USD MILLION)
FIGURE 38. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
FIGURE 39. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY SKIN DISORDERS, 2018-2030 (USD MILLION)
FIGURE 40. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY WOMEN'S HEALTH, 2018-2030 (USD MILLION)
FIGURE 41. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 42. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 43. UNITED STATES HUMAN MICROBIOME MARKET COMPETITIVE STRATEGIC WINDOW, BY APPLICATION, 2030
FIGURE 44. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
FIGURE 45. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
FIGURE 46. CALIFORNIA HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 47. FLORIDA HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 48. ILLINOIS HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 49. NEW YORK HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 50. OHIO HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 51. PENNSYLVANIA HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 52. TEXAS HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 53. UNITED STATES HUMAN MICROBIOME MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 54. UNITED STATES HUMAN MICROBIOME MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 55. UNITED STATES HUMAN MICROBIOME MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022

List of Tables

TABLE 1. UNITED STATES HUMAN MICROBIOME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. UNITED STATES HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 5. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 6. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY ACUTE DIARRHEA, 2018-2030 (USD MILLION)
TABLE 7. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY ACUTE DIARRHEA, BY STATE, 2018-2030 (USD MILLION)
TABLE 8. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 9. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY STATE, 2018-2030 (USD MILLION)
TABLE 10. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 11. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY CANCER, BY STATE, 2018-2030 (USD MILLION)
TABLE 12. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 13. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIABETES, BY STATE, 2018-2030 (USD MILLION)
TABLE 14. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY MENTAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 15. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY MENTAL DISORDERS, BY STATE, 2018-2030 (USD MILLION)
TABLE 16. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY OBESITY, 2018-2030 (USD MILLION)
TABLE 17. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY OBESITY, BY STATE, 2018-2030 (USD MILLION)
TABLE 18. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 19. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY 16S RRNA SEQUENCING, 2018-2030 (USD MILLION)
TABLE 20. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY 16S RRNA SEQUENCING, BY STATE, 2018-2030 (USD MILLION)
TABLE 21. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY CELL CULTURE TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 22. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY STATE, 2018-2030 (USD MILLION)
TABLE 23. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY COMPUTATIONAL TOOLS, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY COMPUTATIONAL TOOLS, BY STATE, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY HIGH-THROUGHPUT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY HIGH-THROUGHPUT TECHNOLOGY, BY STATE, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY METAGENOMIC SEQUENCING, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY METAGENOMIC SEQUENCING, BY STATE, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY OMICS TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY OMICS TECHNOLOGY, BY STATE, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, BY STATE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DRUGS, BY STATE, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY FOODS, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY FOODS, BY STATE, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY PREBIOTIC & PROBIOTICS, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY PREBIOTIC & PROBIOTICS, BY STATE, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY STATE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY METABOLIC DISORDERS, BY STATE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY SKIN DISORDERS, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY SKIN DISORDERS, BY STATE, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY WOMEN'S HEALTH, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY WOMEN'S HEALTH, BY STATE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, BY STATE, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, BY STATE, 2018-2030 (USD MILLION)
TABLE 54. CALIFORNIA HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 55. CALIFORNIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 56. CALIFORNIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 57. CALIFORNIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 58. CALIFORNIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 59. CALIFORNIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. FLORIDA HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 61. FLORIDA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 62. FLORIDA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 63. FLORIDA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 64. FLORIDA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 65. FLORIDA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. ILLINOIS HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 67. ILLINOIS HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 68. ILLINOIS HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 69. ILLINOIS HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 70. ILLINOIS HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 71. ILLINOIS HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. NEW YORK HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 73. NEW YORK HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 74. NEW YORK HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 75. NEW YORK HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 76. NEW YORK HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 77. NEW YORK HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. OHIO HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 79. OHIO HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 80. OHIO HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 81. OHIO HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 82. OHIO HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 83. OHIO HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. PENNSYLVANIA HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 85. PENNSYLVANIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 86. PENNSYLVANIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 87. PENNSYLVANIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 88. PENNSYLVANIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 89. PENNSYLVANIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. TEXAS HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 91. TEXAS HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 92. TEXAS HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 93. TEXAS HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 94. TEXAS HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 95. TEXAS HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES HUMAN MICROBIOME MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 97. UNITED STATES HUMAN MICROBIOME MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 98. UNITED STATES HUMAN MICROBIOME MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 99. UNITED STATES HUMAN MICROBIOME MARKET RANKING, BY KEY PLAYER, 2022
TABLE 100. UNITED STATES HUMAN MICROBIOME MARKET SHARE, BY KEY PLAYER, 2022
TABLE 101. UNITED STATES HUMAN MICROBIOME MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 102. UNITED STATES HUMAN MICROBIOME MARKET MERGER & ACQUISITION
TABLE 103. UNITED STATES HUMAN MICROBIOME MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 104. UNITED STATES HUMAN MICROBIOME MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 105. UNITED STATES HUMAN MICROBIOME MARKET INVESTMENT & FUNDING
TABLE 106. UNITED STATES HUMAN MICROBIOME MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 107. UNITED STATES HUMAN MICROBIOME MARKET: LICENSE & PRICING

Companies Mentioned

4D pharma PLC
AOBiome, LLC
Astarte Medical Partners, Inc
Axial Therapeutics, Inc.
DuPont de Nemours, Inc.
Enterome Bioscience
Evelo Biosciences, Inc.
Exeliom Biosciences SAS
Ferring B.V.
Finch Therapeutics Group, Inc.
Intralytix, Inc.
Locus Biosciences, Inc.
Merck and Co. Inc.
Metabiomics Corporation
Osel Inc.
Second Genome, Inc.
Seres Therapeutics, Inc.
Synlogic, Inc.
Synthetic Biologics, Inc.
Vedanta Biosciences, Inc.
Yakult Honsha Co., Ltd.

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.